Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Nurix Therapeutics (NRIX) Income towards Parent Company: 2019-2024

Historic Income towards Parent Company for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to -$193.6 million.

  • Nurix Therapeutics' Income towards Parent Company fell 76.53% to -$86.4 million in Q3 2025 from the same period last year, while for Aug 2025 it was -$244.8 million, marking a year-over-year decrease of 38.32%. This contributed to the annual value of -$193.6 million for FY2024, which is 34.47% down from last year.
  • Per Nurix Therapeutics' latest filing, its Income towards Parent Company stood at -$193.6 million for FY2024, which was down 34.47% from -$143.9 million recorded in FY2023.
  • Nurix Therapeutics' Income towards Parent Company's 5-year high stood at -$43.2 million during FY2020, with a 5-year trough of -$193.6 million in FY2024.
  • For the 3-year period, Nurix Therapeutics' Income towards Parent Company averaged around -$172.6 million, with its median value being -$180.4 million (2022).
  • In the last 5 years, Nurix Therapeutics' Income towards Parent Company tumbled by 171.28% in 2021 and then grew by 20.19% in 2023.
  • Nurix Therapeutics' Income towards Parent Company (Yearly) stood at -$43.2 million in 2020, then crashed by 171.28% to -$117.2 million in 2021, then plummeted by 53.90% to -$180.4 million in 2022, then climbed by 20.19% to -$143.9 million in 2023, then tumbled by 34.47% to -$193.6 million in 2024.